Clinical study on lacosamide treatment of epilepsy during pregnancy
10.3760/cma.j.cn113694-20240913-00621
- VernacularTitle:癫痫患者妊娠期应用拉考沙胺的临床研究
- Author:
Ying WANG
1
;
Yan ZHANG
;
Xiaoli WANG
;
Bi WANG
;
Na YUAN
;
Xinbo ZHANG
;
Chenwei LI
;
Xinyu WEN
;
Yonghong LIU
Author Information
1. 空军军医大学西京医院神经内科脑电监测中心，西安 710032
- Publication Type:Journal Article
- Keywords:
Epilepsy;
Pregnancy;
Lacosamide
- From:
Chinese Journal of Neurology
2025;58(3):286-291
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effectiveness and safety of lacosamide (LCM) in pregnant women with epilepsy.Methods:A retrospective study was conducted involving 6 pregnant women with epilepsy who were treated with LCM at the Electroencephalogram Monitoring Center of the Department of Neurology, Xijing Hospital of Air Force Military Medical University from January 2022 to June 2023. Their electroclinical characteristics, seizures during pregnancy, breastfeeding, and follow-up were summarized.Results:The 6 patients were aged 22 to 30 years at the time of pregnancy. Three patients were treated with monotherapy, with a daily dose of LCM ranging from 150 mg to 200 mg, while the other 3 patients were treated with combination therapy, with a daily dose of 150 mg. The seizures of 5 patients decreased during pregnancy compared with progestation except for the case 2 without adherence to Medication. No malformations were observed in the newborns, with the Apgar scores of 9-10 at 1 minute and 5 minutes after birth. The infants showed normal growth, development, intelligence, and motor skills in subsequent assessments. Two patients breastfed their infants, 1 for 6 months and the other for 14 months by the last follow-up, with a daily LCM dose of 150 mg to 300 mg during the breastfeeding. No adverse reactions were observed in the infants.Conclusion:The addition of LCM during pregnancy and lactation showed good effectiveness and safety, with no observed birth malformations.
